We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ATX market cap is 16.1M. The company's latest EPS is NZD -0.0232 and P/E is -3.45.
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| NZD ($) | NZD ($) | NZD ($) | NZD ($) | NZD ($) | |
| Total Revenue | 34k | 1.59M | 1.98M | 1.19M | 4.45M |
| Operating Income | -2.23M | -2.28M | -3.64M | -6.29M | -4.57M |
| Net Income | -2.22M | -2.28M | -3.64M | -6.24M | -4.5M |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| NZD ($) | NZD ($) | NZD ($) | NZD ($) | NZD ($) | |
| Total Assets | 9.12M | 10.88M | 24.48M | 18.68M | 14.85M |
| Total Liabilities | 511k | 539k | 2.64M | 2.85M | 3.43M |
| Total Equity | 8.61M | 10.34M | 21.85M | 15.84M | 11.42M |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| NZD ($) | NZD ($) | NZD ($) | NZD ($) | NZD ($) | |
| Operating | -2.09M | -2.92M | -4.4M | -5.29M | -5.13M |
| Investing | N/A | -5k | -26k | -58k | -2k |
| Financing | 1.96M | 3.66M | 17.19M | -84k | -773k |
| Market Cap | 16.1M |
| Price to Earnings Ratio | -3.45 |
| Price to Sales Ratio | 3.48 |
| Price to Cash Ratio | 4.6 |
| Price to Book Ratio | 1.36 |
| Dividend Yield | - |
| Shares Outstanding | 194.01M |
| Average Volume (1 week) | 514.48k |
| Average Volume (1 Month) | 418.58k |
| 52 Week Change | 9.21% |
| 52 Week High | 0.18 |
| 52 Week Low | 0.055 |
| Spread (Intraday) | 0 (2.38%) |
| Company Name | Amplia Therapeutics Limited |
| Address |
level 17 melbourne, victoria 3000 |
| Website | https://www.ampliatx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
